Small Cell Lung Cancer

The ADRIATIC trial found that consolidation therapy with durvalumab improved progression-free survival and overall survival in patients with limited-stage small cell lung cancer, regardless of prior prophylactic cranial irradiation or concurrent chemoradiotherapy use.

The next-generation radiopharmaceutical ABD-147 was previously granted FDA fast track designation in extensive-stage small cell lung cancer.

The bispecific T-cell engager tarlatamab showed continued efficacy and tolerable safety, according to follow-up from the phase 2 DeLLphi-301 study.

Ifinatamab deruxtecan, a novel antibody-drug conjugate, returned promising response rates at both dose levels evaluated among patients with small cell lung cancer.

During an in-person Community Case Forum event, Ticiana Leal, MD, discussed the trials of lurbinectedin and tarlatalamb as therapy for previously treated small cell lung cancer.

Backed by the phase 1 ARTEMIS-001 trial, the FDA has granted GSK5764227 a breakthrough therapy designation for the treatment of extensive-stage small cell lung cancer.

Durvalumab was also granted breakthrough therapy designation for the treatment of patients with limited-stage small cell lung cancer.

KeyVibe-008, a phase 3 study investigating the combination of vibostolimab and pembrolizumab in small cell lung cancer, did not show an improvement in overall survival.

Ayal Aizer, MD, MHS, discussed the changing treatment paradigms of treatment of brain metastases in patients with small cell lung cancer.

The phase 3 IDeate-Lung02 study has dosed its first patient with small cell lung cancer with the investigational antibody-drug conjugate infinatamab deruxtecan.

Small cell lung cancer poses a significant challenge across the world, particularly in low-middle-income countries where it is often associated with poor outcomes.

7MW3711, an innovative antibody-drug conjugate targeting B7-H3, has been granted an orphan drug designation by the FDA for treating small cell lung cancer.

In an interview, Aakash Desai, MD, MPH, discussed significant lung cancer treatment advancements that were highlighted at ASCO 2024.

David Spigel, MD, discussed the findings and implications from the phase 3 ADRIATIC study of durvalumab in small cell lung cancer presented at the 2024 ASCO Annual Meeting.

Lurbinectedin and irinotecan in the second line delivered a favorable risk/benefit profile and high, durable response rates in patients with high risk factors in small cell lung cancer.

While the primary end point of overall survival was not met in the phase 3 RESILIENT study, the overall response rate was 44.1% vs 21.6% with liposomal irinotecan vs topotecan in relapsed small cell lung cancer.

Consolidation treatment with durvalumab after concurrent chemoradiation led to a survival benefit vs placebo for patients with limited-stage small cell lung cancer, leading researchers to argue for a new standard of care in this setting.

In an in-person Community Case Forum event in partnership with the North Carolina Oncology Association and South Carolina Oncology Society, Daniel Carrizosa, MD, MS, discussed the use of the immunotherapies durvalumab and atezolizumab in patients with small cell lung cancer.

In an interview with Targeted Oncology, Joe Leach, MD, highlighted the current state and future prospects of treating patients with small cell lung cancer.

The FDA accelerated approval of tarlatamab makes it the first bispecific T-cell engager therapy for a major solid tumor.

Phase 1 of the Acclaim-3 study evaluating quaratusugene ozeplasmid plus atezolizumab in patients with extensive-stage small cell lung cancer has enrolled and dosed its first patient.

SNB-101, a nanoparticle drug for small cell lung cancer, received a fast track designation from the FDA for expedited development and review.

Updated guidelines for small cell lung cancer were developed with an expert panel assembled by the American Society of Clinical Oncology and Ontario Health.

Adding tislelizumab to chemotherapy improved overall survival and progression-free survival in patients with extensive-stage small cell lung cancer, according to findings from a phase 3 study.

The phase 3 CONVERT study suggests that twice-daily radiotherapy remains the standard for limited-stage small cell lung cancer due to its effectiveness and lower associated toxicity compared to the once-daily approach.

Adding low-dose radiotherapy to standard-of-care durvalumab and chemotherapy led to survival benefits among patients with extensive-stage small cell lung cancer.

PT217 is a first-in-class treatment targeting DLL3 and CD47 for patients with extensive-stage small cell lung cancer.

Findings from a post hoc analysis of lurbinectedin for the treatment of small cell lung cancer showed that the agent was more effective and less toxic than topotecan.

Ariel Lopez-Chavez, MD, provided insights into the current landscape of small cell lung cancer treatment, highlighting approved options and ongoing research.

A phase 2 trial is underway to assess alisertib for extensive-stage small cell lung cancer treatment, aiming to enroll up to 60 patients.